Barclays analyst Gena Wang downgraded PTC Therapeutics to Underweight from Equal Weight while raising her price target for the shares to $26 from $24. The stock closed the trading day up 15c to $26.12. The analyst sees limited upside to 2018 revenue expectations and believes PTC’s growth trajectory is fully priced in at current valuation levels.
previous post